773134-60-4

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 5-bromo-2-methoxybenzoate is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of anti-inflammatory and analgesic drugs. Its chemical structure allows for the creation of medications that can effectively address conditions requiring pain relief and inflammation reduction.
Used in Agrochemical Industry:
In the agrochemical sector, ethyl 5-bromo-2-methoxybenzoate is utilized as an intermediate in the production of compounds that help protect crops from pests and diseases, thereby enhancing agricultural productivity and crop quality.
Used in Fragrance and Flavoring Industry:
Ethyl 5-bromo-2-methoxybenzoate is employed as a building block in the creation of fragrance and flavoring compounds, capitalizing on its unique chemical properties to develop a diverse range of scents and tastes for various consumer products.
Safety Considerations:
Given its potential hazards, ethyl 5-bromo-2-methoxybenzoate is used with strict adherence to safety protocols in controlled laboratory settings to minimize risks associated with ingestion, inhalation, or dermal absorption.

Upstream product

• 64-17-5 ethanol 
• 2476-35-9 5-bromo-2-methoxybenzoic acid 
• 89-55-4 5-bromosalicyclic acid 
• 37540-59-3 2-hydroxy-5-bromobenzoic acid ethyl ester 
• 74-88-4 methyl iodide 
• 7335-26-4 ethyl 2-methoxybenzoate 

Downstream Products

• 63987-24-6 2-methoxy-5-phenoxy-benzoic acid 

Relevant academic research and scientific papers

Mechanistic study on iodine-catalyzed aromatic bromination of aryl ethers by N-Bromosuccinimide

Although iodine-catalyzed reaction has rapid advances in recent years, examples on iodine-catalyzed bromination are rare and the mechanism of these reactions remains unclear. Herein, we reported an I2-catalyzed aromatic bromination of aryl ethers by NBS and presented the details of the mechanistic study including kinetic study and the study of kinetic isotope effects. The study revealed that the reaction was actually catalyzed by IBr formed in the induction period, and the rate-determining step was the HBr-elimination of the Wheland intermediate assisted by IBr.

TRIAZOLONE COMPOUNDS AND USES THEREOF

The invention disclosed herein is directed to compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (I), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist.

COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE FORMATION OF AMYLOID FIBRILS

SUMMARY The present invention provides new amyloidogenesis inhibiting compounds of formula (I): in which R1 is a -NRaRb group, where Ra and Rb, independently, are a hydrogen atom or a C1-C